INTRODUCTION
Thrombophilia is a blood clotting disorder, which can be inherited or acquired. It could be suspected in cases of venous thromboembolism, ischemic stroke, especially in cases of early onset, recurrent thrombotic episodes, family history, etc [1] . It has been also investigated as a risk factor for recurrent miscarriage [2] .
Inherited thrombophilia is responsible for more than 40% of idiopathic thromboembolic events [2] . Possible causes of inherited thrombophilia are antithrombin III, protein C, protein S deficiency or a mutation in factor V Leiden (F V), factor II prothrombin (F II), plasminogen activator inhibitor (PAI) and methylenetetrahydrofolate reductase (MTHFR) genes [3] . F V Leiden is considered a major risk factor for predisposition to thrombophilia. A substitution of arginine with glutamine at position 506 in the factor V causes resistance to activated protein C and it is found in around 5% of Caucasians [4, 5] .
Mutation, caused by replacement of guanosine with adenosine in the gene, coding F II, is associated with elevated levels of prothrombin in the blood [6] and has a frequency distribution of around 2.3% in Caucasians from European descent [7] . The 4G/4G polymorphism of PAI correlates with an increased risk for venous thrombosis due to higher PAI-1 plasma levels and defected fibronolysis of the clot [8] . MTHFR is an enzyme, which has a crucial role in the metabolism of homocysteine by converting it into methionine [9] . However, the C677T polymorhism in the gene, coding MTHFR, causes an impaired function of the enzyme, higher levels of homocysteine and a potentially increased risk for thrombosis [10] .
These genetic polymorphisms could be associated with microthrombosis in the placenta or trophoblast, deep venous thrombosis and stroke. Despite the fact that the results from different studies are controversial, the genetic tests for inherited thrombophilia are requested by clinicians in cases of deep venous thrombosis and unexplained recurrent miscarriages.
The aim of this study is to analyze the frequency distribution of these mutations in patients with vascular disorders (VDs) and recurrent pregnancy loss (RPL), and to evaluate the role of studied polymorphisms as a risk factor for vascular disorders and infertility.
MATERIALS AND METHODS
A total of 200 patients divided into two groups were analyzed between June 2016 and May 2019 in the Laboratory of Medical Genetics in Varna, Bulgaria. Informed consent was obtained from all participants in the study prior to the analysis. First group consisted of 39 female and 38 male patients with vascular disorders such as deep venous thrombosis, pulmonary embolism, stroke, etc. The second group included 124 women with primary infertility, two or more recurrent miscarriages between 8 th and 12 th gestational week and without any anatomical, infectious, or endocrine diseases.
Genomic DNA samples from the individuals were extracted from peripheral blood by a salting out procedure and genotyped for F V Leiden (G1691A), F II (G20210A), PAI 4G/5G, and MTHFR (C677T) polymorphisms using Real time polymerase chain reaction (RT -PCR) (QuantStudio Dx, Applied Biosystems, USA) according to the manufacturer protocol (Generi Biotech).
Differences between the two groups were analyzed by Graphpad Prism software (version 8) using Chi-square test. The chi-square calculations are only valid when all expected values are greater than 1.0 and at least 20% of the expected values are greater than 5. A two-tailed p-value was used and a difference was considered significant at a p value < 0.05. The allelic frequencies for F V, F II and MTHFR polymorphisms were extracted from gnomAD database and used to determine the genotype frequencies by applying the Hardy-Weinberg equation.
RESULTS
The median age of the participants with VDs was 38.95 (standard deviation, SD = 17.55) and of the women with recurrent miscarriges was 32.62 years (SD = 5.83). The VDs group consisted of 39 (50.6%) female and 38 (49.4%) male patients. Main indications for testing were deep vein thrombosis of upper or lower extremities -39 (51.3%), and ischemic stroke -18 (23.7%). The rest 19 (25%) referral diagnoses included pulmonary embolism, thrombosis of the splanchnic veins or sinus cavernosus, retinal vein occlusion, spinal stroke and leucoencephalopathy.
From all investigated women with RPL 83 (67.0%) had two miscarriages, the rest 41(33.0%) had three or more.
There was one (1.3%) homozygote for the mutant allele for F V Leiden (G1691A) and fifteen (19.7%) heterozogytes in VDs group. In the RPL group there were eleven (8.9%) heterozygotes and one (0.8%) homozygote. There was a statistically significant difference (Chi-square, df 4.993, 1; p = 0.0254) between the two groups for the F V polymorphism.
For F II there were 6 (7.9%) heterozygotes from the VDs and and 3 (2.4%) from the RPL group. No homozygotes for the mutant for F II (G20210A) allele were found in both groups. There was no statistical difference between the analyzed patients (Chi-square, df 3.287, 1, p = 0.0698).
The results for the PAI polymorphism showed 38 (53.5%) 4G/5G heterozygotes and 14 (19.7%) 4G/4G homozygotes for the mutant allele from the VDs group. For the RPL group their number was 67 (54.5%) and 32 (26.0%) respectively. The data from the chi-square tests did not differ statistically (Chi-square, df 1.828, 2; p = 0.4010).
32 (47.0%) patients from the VDS group were proved to be heterozygote carriers for the MTHFR (C677T) polymorphism and 7 (10.6%) -homozygotes for the mutant MTHFR (C677T) allele. For the RPL group the distrubtion was 48 (39.3%) and 15 (12.3%) respectively. The data from the chi-square tests did not differ statistically (Chi-square test, df 1.114, 2; p = 0.5729) ( Table 1 ).
In the VDs group there were 13 (18.3%) participants, who were isolated homozygous carriers of the PAI mutant allele and from the RPL group there were 28 (22.8%) women. The number of homozygotes only for the mutated MTHFR alleles in the VDs group was 6 (7.9%) and in the other group -11 (9.0%).
The allelic frequencies and the expected genotype frequencies of the three polymorphisms were calculated according to Hardy-Weinberg equilibrium ( Table 2 ). The percentages of the homozygotes for F V and F II were higher than expected in the two groups of patients. For the MTHFR there was no difference. 
DISCUSSION
Testing for thrombophilia in patients with vascular disorders is controversial and there are no clear guidelines. According to the American Society of Hematologists it should be avoided, if the patients have other risk factors such as surgery or trauma [11] . The patients in the VDs group had no other risk factors. Only one patient reported family history of VTE. However, if these are absent and if the patient is young, with family history of VTE, it is suggested to test for hereditary thrombophilia [12, 13] . This recommendation is also supported by the fact that carrying at least one genetic defect increases about 4 times the thrombogenic risk compared to non-carriers [14] . Moreover, this genetic analysis could be used in patients with both hereditary thrombophilia and antiphospholipid syndrome since this combination increases siginificantly the risk for thrombotic accidents [15] .
According to ESHRE guideline for RPL testing for hereditary thrombophilia is not suggested unless the women have other risk factors, such as family history of hereditary thrombophilia or previous venous thromboembolism (VTE) [16] . However, according to a research, conducted among 154 Bulgarian women with single embryonic loss and 100 healthy controls, it was concluded that F V Leiden had an impact on adverse pregnancy outcomes, especially in the second and third trimester [17] . F V could have a potential effect on the recurrent miscarriage according to other research groups [18, 19] . Moreover, it is suggested as a risk factor for women, having primary infertility [20] , which is also the case in our studied group.
In order to compare the role of F V Leiden among the two studied groups, we performed a chi-square test. The chi-square calculations are only valid when all expected values are greater than 1.0 and at least 20% of the expected values are greater than 5. These conditions have not been met for the results for F V Leiden. That is why we excluded the homozygotes for the mutant allele because their number was equal. Since chi-square test calculates an approximate p value, we also applied the Fisher's exact test and there was a significant difference (p = 0.0309). After analyzing the frequncies of this F V (G1691A) polymorphism among the studied groups, we concluded that this allele was more frequent among the group of patients with vaslucar disorders. These findings correlate with another research study, which concluded that the group with a history of deep vein thrombosis had higher percentages of all studied thrombophilic polymorphisms, compared to women with RPL and control patients [21] . According to the results from our study F V Leiden polymorphism could have a potential aggravating effect, especially on the risk of vascular disoders, since it is more common among the VDs group.
For F II, PAI and MTHFR polymorphisms we did not find any statistical difference betweeen the two studied groups. This is in contradiction to the results from the study of Coulam et al., who found an increase of these polymorphisms among the group with deep vein thrombosis when compared with women with recurrent miscarriages [21] . A possible explanation is the difference in the cohort 24 of patients since their studied groups consisted of 550 women experiencing recurrent miscarriage compared with 43 individuals with a history of deep vein thrombosis. Our group of patients with vascular disoders was more heterogenous, which could be the reason for this finding. In the present study F II, PAI and MTHFR had uncertain predicitve value. F V Leiden remains the mutant allele with the biggest impact on inherited thrombophilia [22] . However, this is a single center study and more patients from different centers should be included.
Two patients from the VDs group and one from the RPL group were combined heterozygote carriers for F V and F II variants. This combined genotype could be a higher risk factor for thromobotic accidents since such patients had thrombosis at a significantly younger age compared to other cases [23, 24] . However, due to the restricted number of combined heterozygotes we cannot estimate if there is a correlation.
Additionaly, the role of the mutant alleles for PAI and MTHFR as isolated risk factors was analyzed. The percentage of isolated carriers of PAI mutant allele was higher in the RPL group -28 (22.8%) people compared to 13 (18.3%) in the VDs group. It was the opposite for the homozygotes only for the mutated MTHFR alleles -11 (7.9%) participants from the RPL group and 6 (9.0%) the other group. However, after comparing the role of the isolated homozygous state for any of these two polymorphisms, the results were statistically nonsignificant (Chi-square, df 0.07019.1; p = 0.7911). This corresponds with findings from other studies, which exclude their isolated role as possible risk factors for vascular disorders or RPL [25, 26] .
From the 15 heterozygotes for F V Leiden in the VDs group 3 (20.0%) patients were isolated carriers of this variant, 8 (53.3%) patients are heterozygotes for F V and one additional factor (PAI or MTHFR), and there were 4 (26.7) patients, who were heterozygotes for all three polymorphisms. However, the sample size of participants with coexistence of different thrombophilic variants is too small to estimate the additive effect.
There were 11 herozygotes for F V in the RSA group and only one woman (9.1%) showed no mutant alleles for the other factors. Five women (45.5%) were heterozygotes for F V and one additional factor (PAI or MTHFR). Two women (18.2%) had a coexistence of heterozygosity for F V together with homozygous state for the mutant allele for both PAI and MTHFR. Three women were combined heterozygotes for F V, PAI and MTHFR variants. However, the number of miscarriages was not increased significantly and was to two abortions. A larger number of participants is needed to evaluate the cumulative effect of the thrombophilic variants.
We also compared the frequency distribution for F V, F II and MTHFR among our studied groups and the expected genotype frequencies. The allelic frequencies were obtained from gnom AD database, which includes 141 456 unrelated individuals sequenced [27] .
There was no data for F II for Bulgarians and information about the distrubution among Europeans (Nonfinnish) was used. There were no allelic frequencies for PAI listed in the database for different populations.
For F V the data showed an increase percentage of homozygotes and heterozygotes in both studied groups, as for F II -only in the VDs group. This confirms findings from previous studies, that F V and F II could have potential impact on thrombotic accidents [28] . For the MTHFR there was no difference between the expected and calculated genotype frequencies in the studied population.
MTHFR may not be a risk factor for inherited thrombophilia and more studies are needed [29, 30] . Moreover, the American College of Medical Genetics and Genomics' states that MTHFR mutations should never be included in any thrombophilia panel [31] .
There were no listed allele frequencies of PAI in the genomic databases and we were unable to calculate the genotype frequecies.That is why we cannot conclude if PAI is a risk factor for vascular disorders or RPL. In spite of that, in a study by Adler, G., et al. there was a statistically significant association between carrying 4G allele and RPL in Bulgarian women (p = 0.018) [32] . However, there is no guideline, suggesting to include PAI polymorphisms in the thrombophilia panel and more studies are needed to prove this finding in the Bulgarian population.
The patients included in the study were not tested for other thrombophilias such as antiphospholipid antibodies, protein C and S deficiency, etc., which could be considered as a possible limitation of the research. Further experiments are needed to evaluate the role of other thrombophilic risk factors.
Testing for thrombophilia has evolved rapidly from its beginning in the 1990s. Today, the benefits of this analysis are controversial and the recommendations state to do the test only in specific risk groups [33] . Despite of the limited impact that these analyses might have on the treatment process, clinicians often recommend testing for thrombophilia, including other factors with limited predictive value [34] . Nevertheless, F V Leiden remains the strongest factor for vascular disorders and RPL [19, 35] .
